Papamichael K - Search Results

1

Infliximab in inflammatory bowel disease.

Papamichael K, Lin S, Moore M, Papaioannou G, Sattler L, Cheifetz AS. Papamichael K, et al. Ther Adv Chronic Dis. 2019 Mar 26;10:2040622319838443. doi: 10.1177/2040622319838443. eCollection 2019. Ther Adv Chronic Dis. 2019. PMID: 30937157 Free PMC article. Review.

2

Higher Adalimumab Drug Levels Are Associated with Mucosal Healing in Patients with Crohn's Disease.

Papamichael K, Cheifetz AS. Papamichael K, et al. J Crohns Colitis. 2016 May;10(5):507-9. doi: 10.1093/ecco-jcc/jjw041. Epub 2016 Feb 13. J Crohns Colitis. 2016. PMID: 26874348 Free PMC article. No abstract available.

3

Therapeutic Drug Monitoring in IBD: The New Standard-of-Care for Anti-TNF Therapy.

Papamichael K, Cheifetz AS. Papamichael K, et al. Am J Gastroenterol. 2017 May;112(5):673-676. doi: 10.1038/ajg.2017.21. Epub 2017 Feb 21. Am J Gastroenterol. 2017. PMID: 28220781 Review. No abstract available.

4

Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.

Papamichael K, Chachu KA, Vajravelu RK, Vaughn BP, Ni J, Osterman MT, Cheifetz AS. Papamichael K, et al. Clin Gastroenterol Hepatol. 2017 Oct;15(10):1580-1588.e3. doi: 10.1016/j.cgh.2017.03.031. Epub 2017 Mar 30. Clin Gastroenterol Hepatol. 2017. PMID: 28365486 Free PMC article.

5

Editorial: therapeutic de-escalation of anti-tumour necrosis factor therapy - is less enough?

Papamichael K, Cheifetz AS. Papamichael K, et al. Aliment Pharmacol Ther. 2017 May;45(9):1265-1266. doi: 10.1111/apt.14000. Aliment Pharmacol Ther. 2017. PMID: 28370052 No abstract available.

6

Reply.

Papamichael K, Osterman MT, Cheifetz AS. Papamichael K, et al. Clin Gastroenterol Hepatol. 2017 Oct;15(10):1638-1639. doi: 10.1016/j.cgh.2017.06.004. Epub 2017 Jun 8. Clin Gastroenterol Hepatol. 2017. PMID: 28603051 No abstract available.

7

Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window.

Papamichael K, Vande Casteele N, Ferrante M, Gils A, Cheifetz AS. Papamichael K, et al. Inflamm Bowel Dis. 2017 Sep;23(9):1510-1515. doi: 10.1097/MIB.0000000000001231. Inflamm Bowel Dis. 2017. PMID: 28816757 Review.

8

Use of anti-TNF drug levels to optimise patient management.

Papamichael K, Cheifetz AS. Papamichael K, et al. Frontline Gastroenterol. 2016 Oct;7(4):289-300. doi: 10.1136/flgastro-2016-100685. Epub 2016 Feb 26. Frontline Gastroenterol. 2016. PMID: 28839870 Free PMC article. Review.

9

Histological healing beyond endoscopic healing in ulcerative colitis: Shall we target the "ultra-deep" remission?

Katsanos KH, Papamichael K, Christodoulou DK, Cheifetz AS. Katsanos KH, et al. Among authors: papamichael k. Dig Liver Dis. 2017 Dec;49(12):1332-1333. doi: 10.1016/j.dld.2017.08.043. Epub 2017 Sep 18. Dig Liver Dis. 2017. PMID: 28964677 No abstract available.

10

Defining and predicting deep remission in patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapy.

Papamichael K, Cheifetz AS. Papamichael K, et al. World J Gastroenterol. 2017 Sep 14;23(34):6197-6200. doi: 10.3748/wjg.v23.i34.6197. World J Gastroenterol. 2017. PMID: 28974885 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

143 results

Search Page